Background: Type 1 diabetes involves a multiple decision making process on a daily basis.Mobile technology has been widely spread not only as a mean of communication, but also as multi-usage tool involving a large variety of applications, making everyday life more convenient. “D-Partner” (Diabetes Innovations Ltd) is a mobile based application that serves as a self-management tool for type 1 diabetes, including a bolus wizard (with food database),a basal insulin titration manager, as well as, a large number of automated notifications, warnings or reward messages, according to the data imported by the patient. In addition,“D-Partner” serves as a telemedicine tool, as information of meals, insulin dosage, measurements of glucose, blood pressure, body weight, and lab values, may be monitored by the physician through an on-line, web-based platform.
Aim: To investigate the efficacy of "D-Partner" mobile application, in glucose management, in patients with type 1 diabetes.
Methods: 24 patients with type 1 diabetes (14 male, 10 female), with diabetes duration of 14,2±8,8 years, mean age of 37.4±11,7 years and HBA1c >7%, on basal bolus insulin therapy, were randomized to receive either standard care, or standard care plus the ‘D-Partner” application usage. HBA1c, somatometric data, blood pressure, heart rate and hypoglycemia frequency data, were obtained at baseline and 3 months after the intervention.
Results: The intervention group presented a significantly improved glucose control as recorded by HBA1c reduction, compared to the control group (p=0.01). Additionally, hypoglycemia incidence was significantly lower in the intervention group (p=0.04). There were no significant changes in somatometric data blood pressure, and heart rate, among the 2 groups.
Concusion: D-partner, is a mobile based self-management application, that may contribute to a better management of type 1 diabetes, potentially improving the life quality of the patient.
J. Doupis: Consultant; Self; Novo Nordisk Inc., Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc.. V. Papandreopoulou: None. S. Glykofridi: None. V. Andrianesis: None.